Molecular Quantification of Insulin mRNA
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00324207|
Recruitment Status : Completed
First Posted : May 10, 2006
Last Update Posted : March 5, 2010
The objectives of this study are to:
- quantitate the level of insulin mRNA in the while cell fraction of whole blood in selected groups of subjects,
- determine the gene expression of markers of white cell activation in the white cell fraction of whole blood in selected subjects,
- determine the identity of the white cell responsible for expression of insulin mRNA and
- determine protein expression of mRNA of insulin/proinsulin and selected genes of white cell activation.
|Condition or disease|
|Type 1 Diabetes Mellitus|
Indicators of active immune or chemically mediated beta cell destruction would be helpful for predicting the development and severity of autoimmune diabetes and monitoring the success of islet transplants. Currently there are no reliable indicators readily available.
Insulin mRNA in the white cell fraction of blood has been detected or elevated under several circumstances including:
- normal animals
- after islet cell transplantation
- hyperglycemic induced expression and
- during induction of diabetes with streptozotocin
The investigators propose that quantitative measurement of insulin mRNA may be an accurate, innovative and minimally invasive indicator of beta cell destruction.
|Study Type :||Observational|
|Estimated Enrollment :||400 participants|
|Official Title:||Prediction of Type 1 Diabetes: Molecular Quantification of Insulin mRNA in the While Cell Fraction of Whole Blood|
|Study Start Date :||February 2006|
|Actual Primary Completion Date :||January 2009|
|Actual Study Completion Date :||January 2009|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00324207
|United States, Missouri|
|Children's Mercy Hospital|
|Kansas City, Missouri, United States, 64108|
|Principal Investigator:||Wayne Moore, MD, PhD||Children's Mercy Hospital|